VICARIOUS SURGICAL INC (RBOT)
OTCHealth CareMedical - DevicesSnapshot 2026-09-04
$0.04-13.99%
Close 2026-09-04 · 1-day change
OTCHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Reduce operating losses to $9.3 million by 2025-Q4: metric not reported.
The company aims to cut cash burn from $50M in 2025 to $19M in 2026. Operating losses have improved from $16.1M to $9.3M over eight quarters. Leadership is working to stabilize after recent executive changes. These steps could help the company survive and improve.
Cash burn may not fall to $19M as planned. Operating losses might stay high or worsen. Executive departures could hurt leadership and execution. The company faces risks from delisting and trading suspension.
The market is selling off sharply, reflecting high risk and uncertainty. No clear consensus or fair value is available. The price likely prices in ongoing losses and leadership instability.
Breaks if: CFO position remains vacant beyond 2026-Q3
Address recent CEO, CFO, and board member departures to maintain leadership continuity and company stability.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on reducing cash burn and improving financial stability, which is essential for its long-term success.
The market seems to be pricing in a cautious outlook given the company's current losses and management volatility. However, the recent financial performance is better than many peers, suggesting some optimism is still present.
Management is working to reduce cash burn to $19 million in 2026 and has shown gradual improvement in operating losses. However, the high-risk environment and ongoing executive transitions could create uncertainty in the near term.
The thesis hinges on the company's ability to manage guidance effectively in upcoming calls and navigate the broader economic landscape, particularly if recession fears grow. Additionally, performance of sector leaders could influence RBOT's trajectory.
The most important moves since the prior daily snapshot.
Total stock risk fell by 16.4 points (from 100.0 to 83.6).
Market risk fell by 16.4 points (from 100.0 to 83.6).
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. Management disclosed multiple key executive departures including CEO and CFO in 2026-Q2 and Q3. The company is actively managing leadership transitions amid these changes, with mixed progress on stability.
“CEO, President, CTO, CMO, and board members resigned or were terminated as part of company transition.”
“Chief Financial Officer Sarah Romano resigned without a successor named.”
Breaks if: cash burn exceeds $19 million in FY26
Continue efforts to reduce cash burn from prior years to approximately $19 million for full-year 2026.
Stated as a priority in 3 of last 3 quarters. Management reduced full-year cash burn guidance from $50 million in 2025-Q3 to $35 million in 2025-Q4, then to $19 million in 2026-Q1. The trajectory shows delivering significant improvement in cash burn reduction.
“Vicarious Surgical currently expects full year 2026 cash burn of approximately $19 million.”
“Vicarious Surgical expects full-year 2026 cash burn of approximately $35 million, a $10 million improvement from 2025 guidance of $45 million.”
“Vicarious Surgical expects full year 2025 cash burn of approximately $50 million.”
Breaks if: operating losses exceed $9.3 million in 2025-Q4
Focus on controlling operating losses and improving overall financial condition amid ongoing negative net income.
Stated in 4 of last 4 quarters. Operating losses improved from -$15.7M in 2025-Q1 to -$9.3M in 2025-Q4; net losses improved from -$15.4M to -$10.5M over the same period. Management continues focus on financial stability with a trajectory of gradual improvement.
“Operating income was negative $9.3 million and net income negative $10.5 million.”
“Operating income was negative $11.5 million and net income negative $11.1 million.”
“Operating income was negative $13.5 million and net income negative $13.2 million.”
“Operating income was negative $15.7 million and net income negative $15.4 million.”
In the next 1 to 3 years, RBOT's success will depend on its management execution and external economic factors. Not investment advice.